Quick Answer
MAXCYTE, INC. reported Cash and Equivalents of $20.07 million for fiscal year 2025.
MAXCYTE, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.07M | -28.0% |
| 2024 | $27.88M | -40.0% |
| 2023 | $46.51M | +320.3% |
| 2022 | $11.06M | -76.8% |
| 2021 | $47.78M | +154.8% |
| 2020 | $18.76M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.97M | -64.9% | -14.8% |
| June 30, 2025 | $15.22M | -59.4% | -34.9% |
| March 31, 2025 | $23.39M | +5.1% | -16.1% |
| December 31, 2024 | $27.88M | -40.0% | -24.6% |
| September 30, 2024 | $36.96M | -24.8% | -1.5% |
| June 30, 2024 | $37.51M | -31.2% | +68.6% |
| March 31, 2024 | $22.25M | -41.2% | -52.2% |
| December 31, 2023 | $46.51M | +320.3% | -5.4% |
- MAXCYTE, INC. showed a decrease of -28.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, MAXCYTE, INC.’s cash and equivalents has grown by 7.0% (from $18.76 million to $20.07 million).
- The most recent figure is from MAXCYTE, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: